David Hutton

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

The results support plan to advance lead program in ABCA4-related retinopathies into the clinic in 2024 and expansion into other ophthalmology indications.

According to a University of Florida Health, the researchers used gene therapy to both knock down and replace malfunctioning genetic material that affects light-sensing photoreceptors in the retina.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

For this study, researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.

Cedars-Sinai investigators map changes to the retina that correspond to brain changes in the early stage, opening a path to earlier diagnosis.

MCO-010 has been granted orphan drug designation by the FDA for both diseases and multiple mid- to late-stage clinical trials are ongoing.

According to the company, the award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.

David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024

Saunders is returning to Bausch + Lomb after having served at the company as CEO from 2010 to 2013.

The trial could prove to be a key development in the treatment of people with the rare inherited condition RP, which currently has no approved cure or standard treatment.

If approved by the FDA later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.

Retina specialists help educate the public to take steps to protect their vision during AMD Awareness Month.

Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”

According to Regeneron, aflibercept injection is now approved to treat five retinal conditions caused by ocular angiogenesis.

According to investigators, the new discovery enhances our understanding of the previously unknown function of genomic regions outside the genes.

The Phase 2 SPECTRA clinical trial will assess 4D-150 in patients with DME.

The vision care company is joining forces with the global nonprofit to fight avoidable blindness around the world.

According to the company, ONL1204 is a first-in-class small molecule Fas inhibitor with a mechanism of action designed to provide neuroprotection for retinal cells.